Biospecimen Repository - Division of Epidemiology, Statistics & Prevention Res.

尤尼斯·肯尼迪·施莱弗国家儿童健康和人类发展研究所(NICHD)的流行病学、统计和预防研究部门(以下简称部门)成立了一个内部委员会--生物信息库访问和数据共享委员会(BRADSC)，以监督存储库访问和数据共享计划。简而言之，布拉德委员会将从以下方面对提交的生物检疫提案进行评价：研究问题与当前研究的相关性；研究设计是否足以解决这一问题；来源研究和进行新研究的材料的可行性和适当性；分析的适当性，包括分析物在长期储存下稳定的证据；以及研究人员进行类似研究的经验。 使用该司资源的途径在该司的网站上公布。公告和当前的提案指南可在http://despr.nichd.nih.gov，的研究链接下获得，感兴趣的研究人员应查阅该司的网站，以获取可用的资源、最新的提案提交和评估指南以及费用时间表。根据样本的年龄和性质以及最初的机构审查委员会(IRB)的批准，程序可能会有所不同，尽管程序的总体大纲应该保持不变。根据请求的性质和复杂性，费用时间表可能会有所不同。 目前在该计划下可获得的标本和辅助数据来自国家围产期合作项目(CPP，1959-1966年)、挪威-阿拉巴马州胎儿生长研究(1986-1988年)、阴道感染和早产研究(VIP，1984-)、预防先兆子痫钙试验(CPEP，1992年-1997年)和阴道菌群纵向研究(Flora，1999-2002年)。其他收藏品将通过这一机制及时提供。可用于CPP的样本大致数量：198,389份血清，36,215份脐带血；挪威-阿拉巴马州胎儿生长研究：14,408份来自阿拉巴马州的血清，11,817份来自挪威的血清；VIP：30,067份血清；CPEP：14,429份血清，14,331份尿液；菌群：12,404份血清和阴道拭子，3,197份牙周拭子。大多数样品都有多种等分。

The Division of Epidemiology, Statistics and Prevention Research (hereafter, Division) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has established an internal committee, the Biospecimen Repository Access and Data Sharing Committee (BRADSC), to oversee the repository access and data sharing program. In brief, the BRADS Committee will evaluate submitted proposals for biospecimens in terms of their relevance of the study question to current research; adequacy of the study design to address the question; feasibility and appropriateness of the source study and material for conducting the new study; appropriateness of the assay, including evidence that the analyte is stable under prolonged storage; and experience of the investigators in conducting similar studies. Access to Division resources is announced on the Division website. Announcements and current proposal guidelines are available under the Research link at http://despr.nichd.nih.gov, and interested researchers should consult the Division website for resources available, the most recent guidelines for proposal submission and evaluation, and cost schedules. Procedures may vary depending on the age and nature of the samples and original institutional review board (IRB) approval, although the general outline of the procedures should remain the same. Cost schedules may vary depending on the nature and complexity of the request. The specimens and ancillary data that are currently available under this program are those from the national Collaborative Perinatal Project (CPP, 1959-1966), the Norway-Alabama Fetal Growth Study (1986-1988), the Vaginal Infections and Prematurity Study (VIP, 1984-1989), the Calcium for Preeclampsia Prevention Trial (CPEP, 1992-1997), and the Longitudinal Study of Vaginal Flora (FLORA, 1999-2002). Other collections will be made available through this mechanism in a timely fashion. The approximate number of samples available for CPP: 198,389 serum, 36,215 cord bloods; Norway-Alabama Fetal Growth Study: 14,408 serum from Alabama, 11,817 serum from Norway; VIP: 30,067 serum; CPEP: 14,429 serum, 14,331 urine; and FLORA: 12,404 serum and vaginal washes, 3,197 periodontal swabs. Multiple aliquots are available for most samples.